Fundraising FoxAvoro Capital Advisors — 2015 Investments
4 investments dated 2015 · listed companies and verified rows first · show all
Intellia Therapeutics develops in vivo and ex vivo CRISPR/Cas9 gene editing therapies aimed at treating the root causes of severe genetic diseases, with lead candidates for hereditary angioedema and ATTR amyloidosis.
BiotechDeep TechHealthtechCambridge, US
Nessan Bermingham(Founder)inJennifer Doudna(Founder)Jose Rivera(Executive Officer)inJohn Leonard(President and Chief Executive Officer)inJames Basta(Executive Vice President, General Counsel and Corporate Secretary)inEdward Dulac(Executive Vice President, Chief Financial Officer)in
Co-investorsage1Atlas VentureEcoR1 CapitalForesite CapitalOrbiMedRidgeback Capital+1 more
Gilead Sciences is a biopharmaceutical company headquartered in Foster City, California that discovers, develops, and delivers medicines across virology, oncology, and inflammation.
BiotechHealthtechMedical DevicesNewark, US
Harold Van Wart, Ph. D.(Executive Officer, Director)Pol Boudes(Executive Officer)Charles A. McWherter, Ph. D.(Executive Officer)Sujal Shah(Executive Officer)
BoardCarl Goldfischer, M.D.(Director)Kurt von Emster(Director)in
Co-investorsBay City CapitalForesite CapitalVantagePoint Capital PartnersAbingworth
Rocket Pharmaceuticals develops gene therapies to treat patients with rare genetic diseases, focusing on cardiovascular and hematologic disorders.
BiotechDigital HealthMedical Devices
Gaurav Shah(Co-founder & Chief Executive Officer)in
BoardRoderick Wong(Director)inNaveen Yalamanchi(Director)in
Co-investorsBroadview VenturesCivilization Ventures Management, LlcFrazier Life SciencesLifeSci Venture PartnersRTW Investments L.P.
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Therachon
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.